A groundbreaking study led by researchers at Stanford Medicine has uncovered the biological underpinnings of "brain fog" in patients undergoing CAR-T cell therapy, a revolutionary form of cancer treatment. The research, published in the journal Cell, reveals that the cognitive impairments often reported by patients—including forgetfulness and difficulty concentrating—are driven by a specific cellular mechanism that is remarkably consistent across several other conditions, including chemotherapy-induced cognitive impairment and the lingering effects of respiratory infections like COVID-19 and influenza. By identifying the specific role of the brain’s immune cells in this process, the study not only clarifies why these side effects occur but also points toward potential therapeutic interventions that could soon be available to improve the quality of life for cancer survivors.
The Rise of CAR-T Cell Therapy and the Emergence of Cognitive Side Effects
Chimeric antigen receptor T-cell (CAR-T) therapy has fundamentally transformed the landscape of oncology since its initial FDA approval in 2017. The treatment involves a sophisticated bioengineering process: a patient’s own T cells are harvested, genetically modified in a laboratory to express receptors that target specific proteins on the surface of cancer cells, and then reinfused into the patient. Once back in the body, these "living drugs" proliferate and launch a targeted attack on the malignancy.
Initially approved for the treatment of acute lymphoblastic leukemia (ALL), the scope of CAR-T therapy has expanded rapidly. It is now a standard of care for several types of non-Hodgkin lymphoma and multiple myeloma. Ongoing clinical trials are exploring its efficacy in treating solid tumors, including aggressive pediatric brain stem and spinal cord tumors. While the therapy has saved countless lives, particularly among patients who had exhausted all other options, its success has brought new challenges to light.
As more patients achieve long-term remission, clinicians have observed a recurring suite of neurological symptoms. While severe neurotoxicity, known as immune effector cell-associated neurotoxicity syndrome (ICANS), is a well-documented acute risk of CAR-T therapy, the more subtle, long-term cognitive impairments—often described as "brain fog"—have been less understood. Patients frequently report persistent issues with executive function, memory, and mental clarity that can last long after the cancer has been eradicated.
Investigating the Pathophysiology of Immunotherapy-Related Brain Fog
The Stanford-led research team, headed by senior author Michelle Monje, MD, PhD, sought to determine whether CAR-T therapy alone was sufficient to cause these cognitive changes and, if so, what biological processes were responsible. Dr. Monje, a professor of pediatric neuro-oncology and a Howard Hughes Medical Institute investigator, has spent years studying how various cancer treatments affect the developing and adult brain.
To investigate this, the researchers conducted a series of experiments primarily using mouse models. They designed the study to account for the complex variables present in human patients, such as the location of the tumor and the intensity of the immune response. Mice with tumors in various locations—the brain, blood, skin, and bone—were treated with CAR-T cells. Before and after treatment, the researchers utilized standardized cognitive assessments, such as novel object recognition tests and maze navigation, to quantify changes in mental function.
The results were striking. Cognitive impairment occurred in almost all models where CAR-T therapy was administered, regardless of whether the cancer was located inside or outside the central nervous system. The only exception was a specific model of bone cancer that elicited a very low level of systemic inflammation. This led the team to conclude that the cognitive decline was not necessarily caused by the cancer itself, but rather by the systemic immune response triggered by the CAR-T cells.
The Role of Microglia and the Loss of Myelin
The study’s lead authors, Anna Geraghty, PhD, and Lehi Acosta-Alvarez, identified the brain’s resident immune cells, known as microglia, as the primary drivers of the impairment. Microglia act as the brain’s first line of defense, but when they become chronically activated by systemic inflammation, they can become "annoyed" or reactive.
In the wake of CAR-T cell activity, these activated microglia begin to secrete high levels of inflammatory molecules, including cytokines and chemokines. These substances create a hostile environment for other essential brain cells. Specifically, the researchers found that these inflammatory signals disrupt the function of oligodendrocytes. These are the cells responsible for producing and maintaining myelin, the fatty insulation that wraps around nerve fibers (axons).
Myelin is critical for the rapid and efficient transmission of electrical signals throughout the nervous system. When myelin is damaged or its production is hindered, the speed of neural communication slows down. This "de-insulation" of the brain’s wiring manifests clinically as the sluggish thinking and lack of focus characteristic of brain fog.
To validate these findings in humans, the team analyzed postmortem brain tissue from participants in a Stanford clinical trial involving CAR-T therapy for pediatric spinal cord and brain stem tumors. The human samples confirmed the mouse data: the brains of those who had received CAR-T therapy showed clear evidence of microglial activation and oligodendrocyte dysregulation, mirroring the pathophysiology seen in the lab.
A Unifying Principle of Neuroinflammation
One of the most significant aspects of this study is the discovery that CAR-T-related cognitive impairment shares a common pathway with other conditions. Dr. Monje’s previous research had already established that chemotherapy (often called "chemo-brain") and mild respiratory infections like COVID-19 cause cognitive issues through this same microglia-cytokine-oligodendrocyte axis.
"This research further illustrates that there is a unifying principle underpinning brain fog syndromes," Dr. Monje stated. "We found the exact same pathophysiology we’ve seen in brain fog syndromes that occur after chemotherapy, radiation, and mild respiratory COVID-19 or influenza."
This realization is a major step forward for neurology and oncology. It suggests that "brain fog" is not a collection of unrelated symptoms from different causes, but a specific, treatable neurobiological syndrome triggered by systemic inflammation. Whether the inflammation comes from a viral infection or a potent immunotherapy, the brain’s response follows a predictable and now-identifiable pattern.
Potential Strategies for Reversing Cognitive Decline
Having identified the cellular culprit, the Stanford team tested two primary strategies to reverse the damage in mice.
First, they used a pharmacological compound to transiently deplete the population of microglia in the brain. After a two-week period, they allowed the microglia to repopulate. The new generation of microglia returned in a non-reactive, healthy state. Following this "reset" of the brain’s immune environment, the mice showed a complete recovery of cognitive function.
The second strategy involved blocking the specific signals that the activated microglia use to damage the brain. The researchers administered a medication designed to enter the brain and interfere with chemokine signaling by blocking a specific receptor. This targeted approach was also successful in rescuing cognition in the mouse models.
Because the compounds used in these experiments are similar to drugs already in clinical development or existing medications, the transition to human trials could happen relatively quickly. The researchers are currently exploring how to safely adapt these strategies for cancer survivors who are struggling with the long-term effects of their treatment.
Implications for Pediatric Oncology and Quality of Life
The findings are particularly poignant for the field of pediatric oncology. Because children’s brains are still developing, they are especially vulnerable to the effects of neuroinflammation and myelin disruption. As CAR-T therapy becomes more common in treating childhood leukemias and brain tumors, understanding and mitigating these side effects is paramount.
"We’re deeply interested in how cancer therapies affect cognition because it affects patients’ quality of life," Monje emphasized. "And this is especially important for kids because their brains are still developing."
For many survivors, the "cure" for cancer comes at the cost of long-term cognitive hurdles that affect their ability to return to school, hold jobs, or maintain social relationships. By addressing the cognitive side effects of immunotherapy, medical science can move toward a more holistic definition of "recovery"—one that includes the restoration of mental clarity alongside the eradication of the tumor.
Supporting Data and Collaborative Efforts
The study was a massive collaborative effort involving researchers from Stanford University, New York University’s Grossman School of Medicine, and Washington University School of Medicine in St. Louis. The breadth of the study—encompassing multiple cancer models and human tissue validation—provides a robust foundation for the findings.
The research was supported by an extensive list of prestigious organizations, including the National Institutes of Health (NIH), the National Cancer Institute (NCI), the Howard Hughes Medical Institute, and several philanthropic foundations dedicated to pediatric cancer research, such as Alex’s Lemonade Stand Foundation and the McKenna Claire Foundation. This level of support underscores the medical community’s recognition of cognitive health as a frontier in cancer survivorship.
Conclusion: A New Frontier in Neuro-Oncology
The Stanford Medicine study marks a turning point in the study of immunotherapy. As CAR-T cells continue to provide a lifeline for patients with aggressive cancers, the medical community is now equipped with the knowledge to manage the therapy’s impact on the brain.
The identification of a molecular target for brain fog offers hope not only to cancer patients but potentially to millions of individuals suffering from post-viral syndromes and other inflammatory conditions. By focusing on the "annoyed" microglia and the protection of the brain’s myelin, researchers have charted a clear path toward therapeutic interventions that could one day make "brain fog" a preventable or reversible complication of modern medicine. As the research moves toward clinical trials, the goal remains clear: to ensure that surviving cancer does not have to mean sacrificing the cognitive health that defines the human experience.